Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives

Journal of Pharmacology and Experimental Therapeutics

Volumn 288, Issue 3, 1999, Pages 1207-1213

  Gressens, Pierre ^a   Besse, Leslie ^a   Robberecht, Patrick ^a,b   Gozes, Illana ^a,c   Fridkin, Mati ^a,d   Evrard, Philippe ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b FREE UNIVERSITY OF BRUSSELS   (Belgium)

^c TEL AVIV UNIVERSITY   (Israel)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EXCITOTOXIN; GLUTAMIC ACID; IBOTENIC ACID; NORLEUCINE; PROTEINASE; STEARIC ACID; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX LESION; BRAIN CYST; BRAIN DEVELOPMENT; CEREBRAL PALSY; CONTROLLED STUDY; DISEASE SIMULATION; ENCEPHALOMALACIA; FEMALE; INTRACEREBRAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NEUROPROTECTION; NEWBORN; NONHUMAN; PREMATURITY; PRIORITY JOURNAL; WHITE MATTER;

AMINO ACID SEQUENCE; ANIMALS; ANIMALS, NEWBORN; BRAIN; EXCITATORY AMINO ACID AGONISTS; FEMALE; HUMANS; IBOTENIC ACID; INFANT, NEWBORN; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENTRICULAR; LEUKOMALACIA, PERIVENTRICULAR; MALE; MICE; MOLECULAR SEQUENCE DATA; NEUROPROTECTIVE AGENTS; PEPTIDES, CYCLIC; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0032982327     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Brenneman DE and Eiden LE (1986) Vasoactive intestinal peptide and electrical activity influence neuronal survival. Proc Natl Acad Sci USA 83:1159-1162.
2. Brenneman DE, Eiden LE and Siegel RE (1985) Neurotrophic action of VIP on spinal cord cultures. Peptides 6:35-39.
3. Brenneman DE, Westbrook GL, Fitzgerald SP, Ennist DL, Elkins KL, Ruff MR and Pert CD (1988) Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature (London) 335:639-642.
4. Crowley PA (1995) Antenatal corticosteroid therapy: a meta-analysis of the randomized trials 1972 to 1994. Am J Obstet Gynecol 173:322-335.
5. Dibbern DA, Glazner GW, Gozes I, Brenneman DE and Hill JM (1997) Inhibition of murine embryonic growth by human immunodeficiency virus envelope protein and its prevention by vasoactive intestinal peptide and activity-dependent neurotrophic factor. J Clin Invest 99:2837-2841.
6. Edwards AD and Mehmet H (1996) Apoptosis in perinatal hypoxic-ischaemic cerebral damage. Neuropathol Appl Neurobiol 22:494-498.
7. Evrard P, Marret S and Gressens P (1995) Environmental determinants of brain development, with a special emphasis on the excitotoxic cascade at the consecutive developmental steps, in Aktuelle Neuropädiatrie (Rating D ed) pp 22-33, Ciba-Geigy Verlag, Wehr.
8. Evrard P, Miladi N, Bonnier C and Gressens P (1992) Normal and abnormal development of the brain, in Child Neuropsychology, Handbook of Neuropsychology (Rapin I and Segalowitz SJ eds) pp 11-44, Elsevier Science, Amsterdam.
9. 2/PACAP receptors. Eur J Pharmacol 354:105-111.
10. Gourlet P, Vandermeers A, Vandermeers-Piret MC, De Neef P, Waelbroeck M and Robberecht P (1996) Effect of introduction of an arginine 16 in VIP, PACAP and secretin on ligand affinity for the receptors. Biochim Biophys Acta 1314:267-273.
11. Gourlet P, Vertongen P, Vandermeers A, Vandermeers-Piret MC, Rathe J, de Neef P, Waelbroek M and Robberecht P (1997) The long-acting vasoactive intestinal peptide agonist RO 25-1553 is highly selective of the VTP2 receptor subclass. Peptides 18:403-408.
12. Gozes I, Bardea A, Reshef A, Zamostiano R, Zhukovsky S, Rubinraut S, Fridkin M and Brenneman DE (1996) Neuroprotective strategy for Alzheimer's disease: Intranasal administration of a fatty neuropeptide. Proc Natl Acad Sci USA 93:427-432.
13. Gozes I, Fridkin M and Brenneman DE (1995a) Stearyl-Nle-VIP: A non-invasive impotence drug and a potent agent of neuro-protection. Drugs Future 20:680-685.
14. Gozes I, Lilling G, Glazer R, Ticher A, Ashkenazi IE, Davidson A, Rubinraut S, Fridkin M and Brenneman DE (1995b) Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J Pharmacol Exp Ther 273:161-167.
15. Gozes I, Reshef A, Salah D, Rubinraut S and Fridkin M (1994) Stearyl-norleucine-VIP a novel VIP analogue for noninvasive impotence treatment. Endocrinology 134:2121-2125.
16. Gressens P, Hill JM, Gozes I, Fridkin M and Brenneman DE (1993) Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature (London) 362:155-158.
17. Gressens P, Hill JM, Paindaveine B, Gozes I, Fridkin M and Brenneman DE (1994) Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. J Clin Invest 94:2020-2027.
18. Gressens P, Marret S, Hill JM, Brenneman DE, Gozes I, Fridkin M and Evrard P (1997a) Vasoactive intestinal peptide prevent excitotoxic cell death in the murine developing brain. J Clin Invest 100:390-397.
19. Gressens P, Marret S, Martin JL, Laquerrière A, Lombet A and Evrard P (1998) Regulation of neuroprotective action of vasoactive intestinal peptide in the murine developing brain by protein kinase C and mitogen-activated protein kinase cascades: In vivo and in vitro studies. J Neurochem 70:2574-2584.
20. Gressens P, Paindaveine B, Hill JM, Brenneman DE and Evrard P (1997b) Growth factor properties of VIP during early brain development: Whole embryo cultures and in vivo studies. Ann NY Acad Sci 814:152-160.
21. Hagberg B, Hagberg G, Olow I and Wendt LV (1996) The changing panorama of cerebral palsy in Sweden. VII. Prevalence and origin in the birth year period 1987-90. Acta Paediatr 85:954-960.
22. Ishiara T, Shigemoto R, Mori K, Takahashi K and Nagata S (1992) Functional expression and tissue distribution of a novel receptor for vasoactive intestinal peptide. Neuron 8:811-819.
23. 2 receptor: Molecular characterization of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 334:3-8.
24. Marret S, Gressens P, Delpech B, Fessard C and Evrard P (1997) Leukomalacia-like brain lesions in the newborn mouse are prevented by neuromodulators of the N-methyl-D-aspartate glutamatergic receptor and inhibitor of NO° synthesis. Eur J Paediatr Neurol 1:18.
25. Marret S, Gressens P, Gadisseux JF and Evrard P (1995a) Prevention by magnesium of excitotoxic neuronal death in the developing brain: An animal model for clinical intervention. Dev Med Child Neurol 37:473-484.
26. Marret, S, Mukendi R, Gadisseux JF, Gressens P and Evrard P (1995b) Effect of ibotenate on brain development: An excitotoxic mouse model of microgyria and posthypoxic-like lesions. J Neuropathol Exp Neurol 54:358-370.
27. Murphy DJ, Sellers S, MacKenzie IZ, Yudkin PL and Johnson AM (1995) Case-control study of antenatal and intrapartum risk factors for cerebral palsy in very preterm singleton babies. Lancet 346:1449-1454.
28. Nelson KB and Ellenberg JH (1986) Antecedents of cerebral palsy. Multivariate analysis of risk. N Engl J Med 315:81-86.
29. O'Donnell M, Garippa RJ, Rinaldi N, Selig WM, Simko B, Renzetti L, Tannu SA, Wasserman MA, Welton A and Bolin DR (1994) Ro 25-1553: a novel long-acting vasoactive intestinal peptide agonist. Part I: In vitro bronchodilatator studies. J Pharmacol Exp Ther 270:1282-1288.
30. Pharoah P, Cooke T, Cooke RW and Rosenbloom L (1990) Birthweight specific trends in cerebral palsy. Arch Dis Child 65:602-606.
31. Volpe JJ (1995) Neurology of the Newborn. WB Saunders Co., Philadelphia.
32. Zupan V, Gonzalez P, Lacaze-Masmonteil T, Boithias C, d'Allest AM, Dehan M and Gabilan JC (1996) Periventricular leukomalacia: Risk factors revisited. Dev Med Child Neurol 38:1061-1067.
33. 2 receptor in mouse neocortical astrocytogenesis. J Neurochem 70:2165-2173.